A Randomized, Open-Label Phase 1b Study of ME1100 Inhalation Solution Plus Best Available Therapy in the Treatment of Mechanically Ventilated Subjects With Bacterial Pneumonia

Trial Profile

A Randomized, Open-Label Phase 1b Study of ME1100 Inhalation Solution Plus Best Available Therapy in the Treatment of Mechanically Ventilated Subjects With Bacterial Pneumonia

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Arbekacin (Primary)
  • Indications Bacterial infections; Pneumonia
  • Focus Pharmacokinetics
  • Sponsors Meiji Seika Pharma
  • Most Recent Events

    • 03 Jul 2017 Status changed from recruiting to completed.
    • 01 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.
    • 13 May 2016 Study design changed from double blind to open label study. Placebo arm removed from the treatment table hence number of treatment arms changed from 3 to 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top